anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Artificial Intelligence [AI] has been a trendy topic in recent years, with many developed medical applications. In gastrointestinal endoscopy, AI systems include computer-assisted detection [CADe] for lesion detection as bleedings and polyps and computer-assisted diagnosis [CADx] for optical biopsy and lesion characterization. The technology behind these systems is based on a computer algorithm that is trained for a specific function. This function could be to recognize or characterize target lesions such as colonic polyps. Moreover, AI systems can offer technical assistance to improve endoscopic performance as scope insertion guidance. Currently, we believe that such technologies still lack legal and regulatory validations as a large sector of doctors and patients have concerns. However, there is no doubt that these technologies will bring significant improvement in the endoscopic management of patients as well as save money and time.
With the current volatile geopolitical climate, the threat of nuclear assault is high. Exposure to ionizing radiation from either nuclear incidents or radiological accidents often lead to major harmful consequences to human health. Depending on the absorbed dose, the symptoms of the acute radiation syndrome and delayed effects of acute radiation exposure (DEARE) can appear within hours, weeks to months. The lung is a relatively radiosensitive organ with manifestation of radiation pneumonitis as an acute effect, followed by apparent fibrosis in weeks or even months. A recently developed, first-of-its-kind murine model for partial-body irradiation (PBI) injury, which can be used to test potential countermeasures against multi-organ damage such as gastrointestinal (GI) tract and lungs was used for irradiation, with 2.5% bone marrow spared (BM2.5-PBI) from radiation exposure. Long-term damage to lungs from radiation was evaluated using µ-CT scans, pulmonary function testing, histopathological parameters and molecular biomarkers. Pulmonary fibrosis was detected by ground glass opacity observed in µ-CT scans of male and female C57BL/6J mice 6-7 months after BM2.5-PBI. Lung mechanics assessments pertaining to peripheral airways suggested fibrotic lungs with stiffer parenchymal lung tissue and reduced inspiratory capacity in irradiated animals 6-7 months after BM2.5-PBI. Histopathological evaluation of the irradiated lungs revealed presence of focal and diffuse pleural, and parenchymal inflammatory and fibrotic lesions. Fibrosis was confirmed by elevated levels of collagen when compared to lungs of age-matched naïve mice. These findings were validated by findings of elevated levels of pro-fibrotic biomarkers and reduction in anti-inflammatory proteins. In conclusion, a long-term model for radiation-induced pulmonary fibrosis was established, and countermeasures could be screened in this model for survival and protection/mitigation or recovery from radiation-induced pulmonary damage.
The Phase 1 study will enroll two cohorts of 3 XLHED-affected adults each, for a total of 6 subjects. The size and scope of the study design are consistent with a drug development program in an ultra-rare disease and supported by the absence of safety concerns in a GLP non-human primate toxicology study. All subjects must meet entry criteria including documentation of an EDA mutation. Mirroring the conditions of use anticipated for the XLHED-affected newborn study, the adult cohort study incorporates a multiple-dose regimen associated with maximal efficacy in the newborn canine model. Primary outcome measures will be safety, tolerability, immunogenicity and pharmacokinetics (PK). While current data does not support a likelihood of clinical benefit for the XLHED-affected adult subjects, assays of pharmacodynamic/biologic activity are incorporated into the study design as exploratory objectives.
ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
The invention relates to a method for producing a ceramic, a ceramic produced according to said method and to the use thereof. According to the invention, a green body, which consists of at least two different powder mixtures that are compacted to form a moulded body, is initially produced and subsequently sintered. Said powder mixtures respectively contain a ceramic powder and a coloured metal compound and/or a coloured pigment. The two powder mixtures are different in their composition from the coloured metal compound and/or the coloured pigment. The ceramics are shaped prior to sintering and/or during the intermediate step, during which sintering is interrupted and then continued after shaping. The inventive ceramic can be used as colour gradiated dental ceramics or as dental ceramics having a coloured gradient.
PURPOSE:The titled inducer containing T lymphocytes obtained from warm- blooded animals damaged in the liver as an active ingredient. CONSTITUTION:A production inducer for cell growth factor, obtained by containing T lymphocytes, e.g. T lympocytes in body lymphatic tissues, e.g. the thymus, spleen, Bayer's lymphatic tissue, etc., obtained from warm-blooded animals, e.g. rat, mouse, chicken, goat, cattle, rabbit, pig, horse, etc., damaged in the liver as an active ingredient and usable as an injection. A buffer solution, glucose, etc., are added to T lymphocytes and used as a suspension. The above- mentioned inducer is injected into venous vascular systems or abdominal cavities of a normal warm-blooded animal and blood is collected after the lapse of a given time. Blood serum is obtained therefrom and purified to afford the aimed growth factor having a band at 6,000-48,000 molecular weight (according to an electropherogram with SDS polyacrylamide gel) without showing species specificity for animals.
OBJECTIVES: Periodontitis is associated with Fusobacterium nucleatum (F.n) infection. Although the colonization of renal tissue by F.n is well documented, its specific role in kidney disease has yet to be determined. This study aimed to investigate the potential association between F.n-induced periodontitis and renal interstitial fibrosis.
METHODS: The rat gingival sulcus was injected with F.n suspension, while the control group (NC) was injected with PBS. The levels of total protein (TP), albumin (ALB), creatinine, and urea nitrogen (BUN) in rat serum and/or urine were quantified using the appropriate kits. Renal interstitial fibrosis and epithelial-mesenchymal transition (EMT) were evaluated in rats using Masson staining, Periodic Schiff-Methenamine (PASM) staining, and immunohistochemical staining. The levels of fibrosis- and EMT-related proteins and the TGF-β/SMAD2/3 and β-catenin signaling pathways were determined using Western blot analysis. F.n in the kidney tissues was quantitatively determined using bacterial 16S rRNA technology.
RESULTS: Serum levels of TP, ALB, creatinine, and BUN were not significantly decreased in F.n-infected rats with periodontitis. The levels of creatinine and ALB in the urine were not statistically different between two groups. Masson and PASM staining showed that F.n-induced periodontitis could promote renal interstitial fibrosis in rats. The levels of collagen I, fibronectin (FN), vimentin, and α-SMA were upregulated in the kidney tissues of rats with F.n-induced periodontitis and in F.n-treated HK-2 cells. However, E-cadherin levels were reduced. F.n promoted renal interstitial and HK-2 cell fibrosis in rats by modulating the TGF-β/SMAD2/3 and β-catenin signaling pathways. F.n colonization increased renal interstitial fibrosis in rats.
CONCLUSION: F.n-induced periodontitis promoted EMT by activating the TGF-β/SMAD2/3 and β-catenin signaling pathways, thus promoting renal interstitial fibrosis in rats.
BACKGROUND: Ectopic pancreas is a benign subepithelial tumor with an abnormal anatomical position, typically diagnosed incidentally as it does not produce symptoms and is challenging to identify in paraclinical studies. The incidence is very low, so our objective is to present the case of a patient with ectopic pancreas as a rare cause of obscure gastrointestinal bleeding.
CLINICAL CASE: A 70-year-old man presented with melena, anemia, and weight loss. The initial approach involved endoscopic studies (panendoscopy, colonoscopy, enteroscopy), a tagged red blood cell scan and computed tomography, none of which identified the bleeding site. Therefore, an exploratory laparoscopy was performed, revealing a 3 x 3 cm exophytic lesion in the proximal jejunum, which was completely resected. Histopathology confirmed an ectopic pancreas.
CONCLUSIONS: This condition is an uncommon but potentially serious cause of gastrointestinal bleeding, as the definitive diagnosis is often delayed. Therefore, clinical suspicion is crucial for early diagnosis and timely treatment, involving a multidisciplinary team of specialists in gastroenterology, radiology, pathology, and general surgery. In this manuscript, we present one of the few reported cases of ectopic pancreas as the cause of mid-intestinal bleeding.
A tunable medical laser diode system for activating PhotoDynamic Therapy (PDT) compounds is disclosed. A tunable medical laser diode system for activating PhotoDynamic Therapy (PDT) compounds and other moderate or low energy multiple wavelength applications is disclosed. Interchangeable diode laser cartridges are used. Each cartridge contains a diode laser, which consists of at least one diode or diode array or some combination thereof. Typically, each diode laser cartridge is tuned to a different wavelength. Multiple cartridges, however may be tuned to the same wavelength for some applications One or more cartridges are attached to the system base unit simultaneously. The cartridges may be powered in series or in tandem for different applications. Selectively powering these cartridges causes light to be emitted at a certain wavelength or wavelengths. Selection of cartridges is facilitated by a drug identification scanner which scans drug activation wavelength information into the system. The wavelength can then be changed by selecting different cartridge(s) with diodes operating at other wavelengths. Applicator fiber parameters are recognized by the system as are power output and energy density. Modifications of input power are made accordingly. On a finer scale, tuning can be accomplished using a Master Oscillator Power Amplifier (MOPA). Still Finer tuning can be done by adjustment of system operating temperature. The ability to vary output wavelengths allows for multiple PDT compounds to be activated by one laser system. Other medical applications, such as aiding coagulation, may also be performed with diode lasers using the present invention, while retaining the inherent advantages of diode lasers, i.e., simplicity, low cost, and ease of maintenance.
In fish, thermal and hypoxia tolerances may be functionally related, as suggested by the oxygen- and capacity-limited thermal tolerance (OCLTT) concept, which explains performance failure at high temperatures due to limitations in oxygen delivery. In this study the interrelatedness of hyperthermia and hypoxia tolerances in the Nile tilapia (Oreochromis niloticus), and their links to cardiorespiratory traits were examined. Different groups of O. niloticus (n = 51) were subjected to hypoxia and hyperthermia challenges and the O2 tension for aquatic surface respiration (ASR pO2) and critical thermal maximum (CTmax) were assessed as measurement endpoints. Gill filament length, total filament number, ventricle mass, length and width were also measured. Tolerance to hypoxia, as evidenced by ASR pO2 thresholds of the individual fish, was highly variable and varied between 0.26 and 3.39 kPa. ASR events increased more profoundly as O2 tensions decreased below 2 kPa. The CTmax values recorded for the O. niloticus individuals ranged from 43.1 to 44.8 °C (Mean: 44.2 ± 0.4 °C). Remarkably, there was a highly significant correlation between ASR pO2 and CTmax in O. niloticus (r = -0.76, p < 0.0001) with ASR pO2 increasing linearly with decreasing CTmax. There were, however, no discernible relationships between the measured cardiorespiratory properties and hypoxia or hyperthermia tolerances. The strong relationship between hypoxia and hyperthermia tolerances in this study may be related to the ability of the cardiorespiratory system to provide oxygen to respiring tissues under thermal stress, and thus provides some support for the OCLTT concept in this species, at least at the level of the entire organism.
Post-injection delirium/sedation syndrome may occur with each injection of ZYPREXA RELPREVV. Signs and symptoms consistent with olanzapine overdose have been observed, and access to emergency response services must be readily available for safe use [see Boxed Warning and Warnings and Precautions (5.1)]. 

There is no specific antidote to olanzapine. Therefore, appropriate supportive measures should be initiated. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. (Do not use epinephrine, dopamine, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of olanzapine-induced alpha blockade.) Respiratory support, including ventilation, may be required. Close medical supervision and monitoring should continue until the patient recovers. 

The possibility of multiple drug involvement should be considered. In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation, which may include intubation. The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.
INTRODUCTION: The oral cavity harbors an extensive array of over 700 microorganisms, forming the most complex biome of the entire human body, with bacterial species being the most abundant. Oral diseases, e.g. periodontitis and caries, are strictly associated with bacterial dysbiosis. Porphyromonas gingivalis and Streptococcus mutans stand out among bacteria colonizing the oral cavity.
AREAS COVERED: After a brief overview of the bacterial populations in the oral cavity and their roles in regulating (flora) oral cavity or causing diseases like periodontal and cariogenic pathogens, we focused our attention on P. gingivalis and S. mutans, searching for the last-5-year patents dealing with the proposal of new strategies to fight their infections. Following the PRISMA protocol, we filtered the results and analyzed over 100 applied/granted patents, to provide an in-depth insight into this R&D scenario.
EXPERT OPINION: Several antibacterial proposals have been patented in this period, from both chemical - peptides and small molecules - and biological - probiotics and antibodies - sources, along with natural extracts, polymers, and drug delivery systems. Most of the inventors are from China and Korea and their studies also investigated anti-inflammatory and antioxidant effects, being beneficial to oral health through a prophylactic, protective, or curative effect.
The invention discloses a tricyclic diterpenoid compound and a preparation method and application thereof. The tricyclic diterpenoid compound is obtained by taking aralia melanocarpa stems as raw materials through extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation. The molecular formula of the compound is C20H32O4, the compound is named dumetorumane A, and the structural formula of the compound is as shown in the specification. The preparation method comprises the following steps: by taking the aralia melanocarpa stems as the raw materials, carrying out extract leaching, organic solvent extraction, silica gel column chromatography and high pressure liquid chromatography separation so as to obtain the tricyclic diterpenoid compound. The tricyclic diterpenoid compound can be applied to preparation of medicines for preventing and/or treating tumors and can be applied to preparation of medicines for preventing and/or treating human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer. The tricyclic diterpenoid compound has obvious inhibiting effects on human lung adenocarcinoma, human acute promyelocytic leukemia or human breast cancer cell strains, has favorable anti-cancer activity, and can serve as an anti-cancer active ingredient or a lead compound.
OBJECTIVES: I. Evaluate the safety and tolerability of SU5416 in patients with AIDS-related Kaposi's sarcoma. II. Determine the pharmacokinetics of this regimen in these patients. III. Evaluate the antitumor effects and biological activity of this regimen in these patients. IV. Determine the safety of this regimen on HIV replication and immune parameters in these patients.

OUTLINE: This is a dose escalation, multicenter study. Patients receive SU5416 by intravenous injection twice weekly for 4 weeks. Patients may continue treatment for a maximum of 1 year in the absence of disease progression and unacceptable toxicity. In the absence of dose limiting toxicity (DLT) in the first 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of SU5416 on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose (MTD). Six additional patients are treated at the MTD. Patients are followed at 30 days after the last treatment, and every 3 months thereafter.

PROJECTED ACCRUAL: This study will accrue a maximum of 30 patients.
PCT No. PCT/US94/03624 Sec. 371 Date Dec. 1, 1994 Sec. 102(e) Date Dec. 1, 1994 PCT Filed Apr. 1, 1994 PCT Pub. No. WO94/23015 PCT Pub. Date Oct. 13, 1994This invention provides viral and retroviral vectors which comprises a nucleic acid molecule encoding a human cytosolic aldehyde dehydrogenase or a glutamylcysteine synthetase or combinations thereof. Further, this invention provides an isolated mammalian nucleic acid molecule encoding a cytosolic aldehyde dehydrogenase and glutamylecysteine synthetase. In addition, this invention provides a method for reducing the toxic effects of a cyclophosphamide in a subject which comprises replacing the subject's hematopoietic cells with hematopoietic cells having the retroviral vector. Further, this invention provides a method for introducing a selectable marker into a mammalian cell which comprises transfecting the cell with a nucleic acid molecule encoding human cytosolic aldehyde dehydrogenase or glutamylcysteine synthetase. Lastly, this invention provides a method for selecting mammalian cells expressing protein of interest which comprises: a) introducing into the cells a nucleic acid molecule comprising a nucleic acid molecule encoding the protein of interest and the nucleic acid molecule encoding human cytosolic aldehyde dehdrogenase: b) culturing the resulting transfected cells; and c) selecting cells which express human cytosolic aldehyde dehdrogenase.
Studies have shown that adoptive transfer of myeloid-derived suppressor cells (MDSCs) can alleviate various inflammatory diseases, including glomerulonephritis, but the long-term effects of the transferred MDSCs are still unclear. In addition, although glucocorticoids exert immunosuppressive effects on inflammatory diseases by inducing the expansion of MDSCs, the impact of glucocorticoids on the immunosuppressive function of MDSCs and their molecular mechanisms are unclear. In this study, we found that adoptive transfer of MDSCs to doxorubicin-induced focal segmental glomerulosclerosis (FSGS) mice for eight consecutive weeks led to an increase in serum creatinine and proteinuria and aggravation of renal interstitial fibrosis. Similarly, 8 weeks of high-dose dexamethasone administration exacerbated renal interstitial injury and interstitial fibrosis in doxorubicin-induced mice, manifested as an increase in serum creatinine and proteinuria, collagen deposition and α-SMA expression. On this basis, we found that dexamethasone could enhance MDSC expression and secretion of the fibrosis-related cytokines TGF-β and IL-10. Mechanistically, we revealed that dexamethasone promotes the expression of immunoglobulin-like transcription factor 4 (ILT4), which enhances the T-cell inhibitory function of MDSCs and promotes the activation of STAT6, thereby strengthening the expression and secretion of TGF-β and IL-10. Knocking down ILT4 alleviated renal fibrosis caused by adoptive transfer of MDSCs. Therefore, our findings demonstrate that the role and mechanism of dexamethasone mediate the expression and secretion of TGF-β and IL-10 in MDSCs by promoting the expression of ILT4, thereby leading to renal fibrosis.
PURPOSE: An antibacterial composition containing fulvic acid is provided to ensure antibacterial effect in antibiotic resistant strain and to suppress cell wall or membrane synthesis. CONSTITUTION: An antibacterial composition contains fulvic acid as an active ingredient. The fulvic acid is isolated from natural humic substances. The natural humic substance is formed of an erosion product of organic materials in soil and is detected in soil, water, deposit, charcoal, and peat. The natural humic substances are separated to fulvic acid and humic acid by solubility difference in acid. [Reference numerals] (AA) Immediately; (BB) 15 minutes later; (CC) 30 minutes later; (DD) One hour later